Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538304 | 0.83 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| Water SCHEMBL29421423 | 0.82 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| Water SCHEMBL622142 | 0.82 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL22404293 | 0.77 | TLR7 (0.70) | TLR7TLR8NUDT1 | |
| SCHEMBL8123096 | 0.75 | TLR7 (0.49) | TLR7TLR8NUDT1 | |
| SCHEMBL29606142 | 0.73 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL22898779 | 0.73 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL24233531 | 0.72 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL22898723 | 0.72 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL25575011 | 0.71 | TLR7 (0.46) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | AVACTA LIFE SCIENCES, LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | CD47, VCAM1, CD44 | TLR7 1295/4885TLR8 293/4885NUDT1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.